Marker Therapeutics Inc Cash Flow-to-Debt Ratio
Marker Therapeutics Inc cash flow-to-debt ratio. Marker Therapeutics Inc (MRKR) has a Cash Flow-to-Debt Ratio of -1.54x as of June 2026, meaning its operating cash flow of $-3.72 Million could theoretically repay -2% of its total liabilities ($2.42 Million) in one year. Check earnings quality score of Marker Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Marker Therapeutics Inc (1999–2025)
Cash flow-to-debt ratio of Marker Therapeutics Inc from 1999 to 2025. Historical debt coverage capacity for Marker Therapeutics Inc across 27 annual periods. Check Marker Therapeutics Inc (MRKR) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Marker Therapeutics Inc Cash Flow-to-Debt Ratio by Year (1999–2025)
Marker Therapeutics Inc cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Marker Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Marker Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.28x | $-12.01 Million | $2.27 Million | ▼ -67.7% |
| 2024 | -3.15x | $-10.91 Million | $3.46 Million | ▲ +41.1% |
| 2023 | -5.35x | $-16.44 Million | $3.07 Million | ▼ -193.8% |
| 2022 | -1.82x | $-26.97 Million | $14.82 Million | ▼ -61.1% |
| 2021 | -1.13x | $-27.28 Million | $24.15 Million | ▼ -3.0% |
| 2020 | -1.10x | $-20.03 Million | $18.27 Million | ▲ +86.4% |
| 2019 | -8.04x | $-18.28 Million | $2.27 Million | ▼ -55.7% |
| 2018 | -5.16x | $-14.48 Million | $2.80 Million | ▲ +6.8% |
| 2017 | -5.54x | $-8.44 Million | $1.52 Million | ▼ -47.9% |
| 2016 | -3.75x | $-6.51 Million | $1.74 Million | ▼ -2316.8% |
| 2015 | -0.16x | $-4.34 Million | $28.01 Million | ▲ +91.1% |
| 2014 | -1.75x | $-2.19 Million | $1.25 Million | ▼ -2131.6% |
| 2013 | -0.08x | $-694.58K | $8.85 Million | ▲ +71.0% |
| 2012 | -0.27x | $-1.57 Million | $5.77 Million | ▲ +21.3% |
| 2011 | -0.34x | $-1.31 Million | $3.80 Million | ▼ -26.3% |
| 2010 | -0.27x | $-925.04K | $3.39 Million | ▲ +76.0% |
| 2009 | -1.14x | $-1.12 Million | $986.35K | ▼ -389.7% |
| 2008 | -0.23x | $-714.42K | $3.08 Million | ▲ +63.0% |
| 2007 | -0.63x | $-1.23 Million | $1.95 Million | ▼ -66.9% |
| 2006 | -0.38x | $-1.19 Million | $3.15 Million | ▲ +25.5% |
| 2005 | -0.50x | $-1.16 Million | $2.31 Million | ▼ -4.9% |
| 2004 | -0.48x | $-1.21 Million | $2.53 Million | ▲ +86.3% |
| 2003 | -3.52x | $-2.59 Million | $736.95K | ▲ +26.1% |
| 2002 | -4.76x | $-1.41 Million | $295.60K | ▼ -34741.2% |
| 2001 | 0.01x | $2.38K | $173.03K | ▲ +101.1% |
| 2000 | -1.29x | $-879.74K | $682.74K | ▲ +54.2% |
| 1999 | -2.81x | $-815.18K | $289.71K | — |